GSK - BUY IT

GSK engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical and consumer health-related products. Its Pharmaceuticals segment manufactures prescription drugs and vaccines that are used in various therapeutic areas, including central nervous system, respiratory, anti-viral, anti-bacterial, oncology and emesis, metabolic, cardiovascular, and urogenital. This segment primarily offers Seretide/Advair for asthma and chronic obstructive pulmonary disease; Avandia group of products for diabetes, Lamictal for epilepsy and bipolar disorder; Wellbutrin, an anti-depressant; Zofran to prevent nausea and vomiting associated with chemotherapy and radiotherapy for cancer; Valtrex for herpes; Coreg for heart disease; Imigran/Imitrex for migraine and cluster headache, and Flixotide/Flovent, an inhaled steroid for the treatment of inflammation associated with asthma and COPD, as well as vaccines. The company's Consumer Healthcare segment offers over-the-counter medicines, oral care, and nutritional healthcare products. Its products comprise Lucozade energy and sports drinks; Aquafresh and Sensodyne toothpastes and mouthwashes; Panadol,a paracetamol/ acetaminophen analgesic; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in the United States, Europe, Japan, Asia Pacific, the Middle East, Latin America, Africa, and Canada. It has strategic alliances with Theravance, Inc.; Targacept, Inc.; Santaris Pharma A/S; and Anacor Pharmaceuticals, Inc. GlaxoSmithKline also has a research and collaboration agreement with EvoGenix Limited, as well as a collaboration agreement with Synta Pharmaceuticals Corp. to jointly develop and commercialize STA-4783, a small-molecule oxidative stress inducer for the treatment of metastatic melanoma.

Read this article;


http://www.bizjournals.com/triangle/stories/2008/02/18/daily28.html

http://www.earthtimes.org/articles/show/gsk-receives-favorable-recommendation-by-fda-advisory-committee-for-rotarixr,286616.shtml

http://www.thestreet.com/story/10404288/1/fda-panel-blesses-glaxos-rotavirus-vaccine.html

In sum, the chances are very good this drug gets approved by April third and if it does this stock should go up a nice gain.

Get in, make some money.

The Bull